These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 19627170)

  • 41. Treatment rationale and study design for a randomized trial of pemetrexed/carboplatin followed by maintenance pemetrexed versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with advanced non-small-cell lung cancer of nonsquamous histology.
    Zinner RG; Saxman SB; Peng G; Monberg MJ; Ortuzar WI
    Clin Lung Cancer; 2010 Sep; 11(5):352-7. PubMed ID: 20837462
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer.
    Patel JD; Hensing TA; Rademaker A; Hart EM; Blum MG; Milton DT; Bonomi PD
    J Clin Oncol; 2009 Jul; 27(20):3284-9. PubMed ID: 19433684
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.
    Seto T; Kato T; Nishio M; Goto K; Atagi S; Hosomi Y; Yamamoto N; Hida T; Maemondo M; Nakagawa K; Nagase S; Okamoto I; Yamanaka T; Tajima K; Harada R; Fukuoka M; Yamamoto N
    Lancet Oncol; 2014 Oct; 15(11):1236-44. PubMed ID: 25175099
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and safety of bevacizumab-based therapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer in the phase III BO17704 study (AVAiL).
    Leighl NB; Zatloukal P; Mezger J; Ramlau R; Moore N; Reck M; Manegold C
    J Thorac Oncol; 2010 Dec; 5(12):1970-6. PubMed ID: 20978447
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The safety and efficacy of paclitaxel and carboplatin with or without bevacizumab for treating patients with advanced nonsquamous non-small cell lung cancer with interstitial lung disease.
    Shimizu R; Fujimoto D; Kato R; Otoshi T; Kawamura T; Tamai K; Matsumoto T; Nagata K; Otsuka K; Nakagawa A; Otsuka K; Katakami N; Tomii K
    Cancer Chemother Pharmacol; 2014 Dec; 74(6):1159-66. PubMed ID: 25245821
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A phase II study of erlotinib in combination with bevacizumab versus chemotherapy plus bevacizumab in the first-line treatment of advanced non-squamous non-small cell lung cancer.
    Ciuleanu T; Tsai CM; Tsao CJ; Milanowski J; Amoroso D; Heo DS; Groen HJ; Szczesna A; Chung CY; Chao TY; Middleton G; Zeaiter A; Klingelschmitt G; Klughammer B; Thatcher N
    Lung Cancer; 2013 Nov; 82(2):276-81. PubMed ID: 23992877
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Platinum-based doublet chemotherapy plus bevacizumab without bevacizumab maintenance in advanced non-small cell lung cancer (NSCLC).
    Nørøxe DS; Wallerek S; Sørensen JB
    Anticancer Res; 2013 Aug; 33(8):3275-8. PubMed ID: 23898091
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A correlative biomarker analysis of the combination of bevacizumab and carboplatin-based chemotherapy for advanced nonsquamous non-small-cell lung cancer: results of the phase II randomized ABIGAIL study (BO21015).
    Mok T; Gorbunova V; Juhasz E; Szima B; Burdaeva O; Orlov S; Yu CJ; Archer V; Hilton M; Delmar P; Pallaud C; Reck M
    J Thorac Oncol; 2014 Jun; 9(6):848-55. PubMed ID: 24807156
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effectiveness and safety of bevacizumab for unresectable non-small-cell lung cancer: a meta-analysis.
    Yang K; Wang YJ; Chen XR; Chen HN
    Clin Drug Investig; 2010; 30(4):229-41. PubMed ID: 20225906
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Treatment rationale and study design for the pointbreak study: a randomized, open-label phase III study of pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/bevacizumab versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer.
    Patel JD; Bonomi P; Socinski MA; Govindan R; Hong S; Obasaju C; Pennella EJ; Girvan AC; Guba SC
    Clin Lung Cancer; 2009 Jul; 10(4):252-6. PubMed ID: 19632943
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Emerging data with antiangiogenic therapies in early and advanced non-small-cell lung cancer.
    Horn L; Sandler AB
    Clin Lung Cancer; 2009 Mar; 10 Suppl 1(Suppl 1):S7-16. PubMed ID: 19362948
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bevacizumab and non-small-cell lung cancer: starving the enemy to survive.
    Grossi F; Aita M
    Expert Opin Biol Ther; 2007 Jul; 7(7):1107-19. PubMed ID: 17665997
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The role of bevacizumab in the treatment of non-small cell lung cancer: current indications and future developments.
    Gridelli C; Maione P; Rossi A; De Marinis F
    Oncologist; 2007 Oct; 12(10):1183-93. PubMed ID: 17962612
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Paclitaxel-bevacizumab is a possible alternative as salvage chemotherapy in advanced non-small cell bronchial carcinoma].
    Zarza V; Couraud S; Bosc C; Toffart AC; Moro-Sibilot D; Souquet PJ
    Rev Mal Respir; 2014 Sep; 31(7):601-7. PubMed ID: 25239581
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Combination of paclitaxel and bevacizumab in heavily pre-treated non-small-cell lung cancer (NSCLC) patients: a case series study on 15 patients.
    Le Moulec S; Hadoux J; Gontier E; Chargari C; Helissey C; Lamand V; Tanz R; Farace F; Vedrine L; Bonardel G; Soria JC; Besse B
    Bull Cancer; 2013 Dec; 100(12):30-7. PubMed ID: 24316967
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Bevacizumab for the treatment of advanced non-small-cell lung cancer.
    Manegold C
    Expert Rev Anticancer Ther; 2008 May; 8(5):689-99. PubMed ID: 18471042
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non-small cell lung cancer (West Japan Oncology Group 5910L): An open-label, randomized, phase 2 trial.
    Takeda M; Yamanaka T; Seto T; Hayashi H; Azuma K; Okada M; Sugawara S; Daga H; Hirashima T; Yonesaka K; Urata Y; Murakami H; Saito H; Kubo A; Sawa T; Miyahara E; Nogami N; Nakagawa K; Nakanishi Y; Okamoto I
    Cancer; 2016 Apr; 122(7):1050-9. PubMed ID: 26828788
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Randomized phase II study of cetuximab and bevacizumab in combination with two regimens of paclitaxel and carboplatin in chemonaive patients with stage IIIB/IV non-small-cell lung cancer.
    Bonomi PD; Mace J; Mandanas RA; Min M; Olsen M; Youssoufian H; Katz TL; Sheth G; Lee HJ
    J Thorac Oncol; 2013 Mar; 8(3):338-45. PubMed ID: 23370316
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer.
    Lara PN; Douillard JY; Nakagawa K; von Pawel J; McKeage MJ; Albert I; Losonczy G; Reck M; Heo DS; Fan X; Fandi A; Scagliotti G
    J Clin Oncol; 2011 Aug; 29(22):2965-71. PubMed ID: 21709202
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Safety and efficacy of first-line bevacizumab plus chemotherapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer: safety of avastin in lung trial (MO19390).
    Laskin J; Crinò L; Felip E; Franke F; Gorbunova V; Groen H; Jiang GL; Reck M; Schneider CP
    J Thorac Oncol; 2012 Jan; 7(1):203-11. PubMed ID: 22173662
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.